The efficacy and safety of eltrombopag in 13 children with chronic immune thrombocytopenia

VernacularTitle:艾曲泊帕治疗13例儿童慢性原发免疫性血小板减少症的疗效和安全性分析
Author: Yani LUO ¹ ; Wenqian WU ; Hailong HE
Author Information

1. 苏州大学附属儿童医院血液科，苏州　215000
Keywords: Thrombocytopenia; Child; Treatment outcome; Safety; Eltrombopag
From: Chinese Journal of Postgraduates of Medicine 2022;45(11):1042-1045
CountryChina
Language:Chinese
Abstract: Objective:To explore the efficacy and safety of eltrombopag in children with chronic primary immune thrombocytopenia (cITP).Methods:The clinical data of 13 children with cITP in Children′s Hospital of Soochow University from July 2017 to December 2021 were retrospectively analyzed.Results:Among 13 children with cITP, 7 males and 6 females, the median age was 5 years old, the median duration of illness was 2.2 years. The median therapy duration of eltrombopag was 5 months, the median maintenance dose was 25.0 mg/d, the median time to response was 4 weeks; complete response was in 5 cases, partial response was in 2 cases; 2 cases had skin disease, 1 case had arthralgia, 1 case had liver function abnormal, all complications did not cause serious impact.Conclusions:Eltrombopag was an effective and safe therapeutic option for children with cITP.